体内研究 (In Vivo) |
[68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 高表达的 NSCLC 异种移植模型中展现出更优的肿瘤靶向性,其肿瘤摄取峰值达 3.69 %ID/g,肿瘤与肌肉的最大比值为 5.56。 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 靶向 FGFR1 中度表达的 NSCLC 异种移植物,其肿瘤摄取峰值达 3.11 %ID/g,肿瘤与肌肉的最大比值为 4.10。 68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 低表达的 NSCLC 异种移植瘤中的摄取量极低,最大肿瘤摄取率为 1.20 %ID/g,且肿瘤与肌肉的比值较低。 NOTA-cRY9M (静脉注射;单剂量,提前 30 分钟,200 倍过量) 预处理可阻断 Calu-3 异种移植瘤中 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 的 FGFR1 特异性摄取,使肿瘤最大摄取量降至 1.45 %ID/g。 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单次给药) 可特异性靶向 FGFR1 高表达的 NSCLC PDX 肿瘤,其肿瘤摄取峰值达 3.84 %ID/g,肿瘤与肌肉的最大比值为 5.28;过量未标记肽 (200 倍过量;静脉注射;单次给药,提前 30 分钟) 可阻断其摄取。 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单次给药) 在 NSCLC PDX 肿瘤中的摄取与 FGFR1 表达相关,在 PDX-M 肿瘤中呈现中等程度的聚集。 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 低表达的 NSCLC PDX 肿瘤中摄取量极低,与靶标低表达的情况一致。 68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 可特异性靶向 FGFR1 阳性乳腺癌异种移植瘤,其摄取水平与靶标表达相关。 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单次给药) 可特异性靶向 FGFR1 阳性胰腺癌异种移植瘤,其聚集水平与靶标表达量相关。 [68Ga]Ga-NOTA-cRY9M (3.7 MBq;静脉注射;单剂量) 在 FGFR1 低表达乳腺癌异种移植物中摄取量极低,与靶标低表达的情况一致。
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Achieved peak tumor uptake of 3.69 %ID/g at 10 minutes postinjection, with gradual decline to 3.33 %ID/g by 60 minutes. Exhibited primarily renal excretion with low hepatic retention. Reached a maximum tumor-to-muscle ratio of 5.56 at 60 minutes, with tumor-to-liver and tumor-to-lung ratios of approximately 2.3 and 3.3, respectively, at 60 minutes. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million NCI-H520 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Achieved peak tumor uptake of 3.11 %ID/g at 10 minutes postinjection, with subsequent decline. Reached a maximum tumor-to-muscle ratio of 4.10 at 60 minutes. Showed tumor uptake of 2.61 %ID/g at 60 minutes postinjection via ex vivo biodistribution. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million NCI-H2170 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Reached a maximum tumor uptake of 1.20 %ID/g. Maintained a consistently low tumor-to-muscle ratio of ~1.42 throughout the imaging window. Showed tumor uptake of 0.91 %ID/g at 60 minutes postinjection via ex vivo biodistribution. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of 5 million Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to 200−300 mm3 over 1−2 weeks, blocking study with unlabeled NOTA-cRY9M) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M; 200-fold excess unlabeled NOTA-cRY9M |
| Administration: |
i.v.; single dose (tracer); i.v.; single dose (unlabeled peptide, 30 minutes prior to tracer) |
| Result: |
Reduced maximal tumor accumulation to 1.45 %ID/g at 60 minutes postinjection. Reached a tumor-to-muscle ratio of only 1.77 at 60 minutes. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-H, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M; 200-fold excess unlabeled NOTA-cRY9M (blocking study) |
| Administration: |
i.v.; single dose (tracer); i.v.; single dose (unlabeled peptide, 30 minutes prior to tracer, blocking study) |
| Result: |
Achieved peak tumor uptake of 3.84 %ID/g at 10 minutes postinjection. Reached a maximum tumor-to-muscle ratio of 5.28. Reduced tumor uptake to 1.28 %ID/g after pretreatment with unlabeled NOTA-cRY9M. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-M, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Exhibited tumor uptake levels intermediate between PDX-H and PDX-L, with corresponding tumor-to-muscle ratios consistent with FGFR1 expression levels. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, patient-derived xenograft model PDX-L, established via subcutaneous implantation of 3 mm3 NSCLC patient tumor tissue into secondary BALB/c nude mice, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Exhibited minimal tumor uptake, comparable to background levels. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of MDA-MB-231 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Showed significant accumulation in MDA-MB-231 tumors (FGFR1-positive), correlating with FGFR1 expression levels. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of PANC-1 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Showed significant accumulation in PANC-1 tumors (FGFR1-positive), correlating with FGFR1 expression levels. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of MDA-MB-468 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Showed minimal accumulation in MDA-MB-468 tumors (FGFR1-low), correlating with low target expression. |
| Animal Model: |
BALB/c nude mice (male, 4 to 5 weeks old, 18−21 g, subcutaneous inoculation of FGFR1-knockdown Calu-3 cells mixed with 50% Corning Matrigel, tumors grown to appropriate size) |
| Dosage: |
3.7 MBq [68Ga]Ga-NOTA-cRY9M |
| Administration: |
i.v.; single dose |
| Result: |
Exhibited substantial reduction in tracer uptake (1.10 %ID/g) in FGFR1-knockdown Calu-3 xenografts compared to control Calu-3 tumors (3.83 %ID/g). Showed correspondingly lower tumor-to-muscle ratios (2.11 vs 5.89) in FGFR1-knockdown vs control tumors. |
|